Qiagen (NYSE:QGEN) Shares Bought by Private Advisor Group LLC

Private Advisor Group LLC raised its stake in Qiagen (NYSE:QGEN) by 8.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,251 shares of the company’s stock after acquiring an additional 461 shares during the period. Private Advisor Group LLC’s holdings in Qiagen were worth $285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of QGEN. Nuance Investments LLC raised its holdings in shares of Qiagen by 17.3% in the second quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock valued at $216,606,000 after buying an additional 778,005 shares during the last quarter. Earnest Partners LLC raised its holdings in shares of Qiagen by 11.1% in the second quarter. Earnest Partners LLC now owns 3,807,284 shares of the company’s stock valued at $156,441,000 after buying an additional 379,679 shares during the last quarter. DekaBank Deutsche Girozentrale raised its holdings in shares of Qiagen by 12.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock valued at $133,292,000 after buying an additional 353,280 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Qiagen by 16.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,320,088 shares of the company’s stock valued at $105,726,000 after buying an additional 324,417 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Qiagen by 19.7% in the second quarter. Sei Investments Co. now owns 1,696,319 shares of the company’s stock valued at $69,702,000 after buying an additional 278,930 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on QGEN. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Robert W. Baird increased their price target on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Finally, HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.88.

Qiagen Trading Down 0.2 %

Shares of QGEN opened at $43.87 on Thursday. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27. The firm’s 50-day moving average is $44.11 and its two-hundred day moving average is $43.70. Qiagen has a twelve month low of $37.51 and a twelve month high of $47.44. The firm has a market capitalization of $10.01 billion, a P/E ratio of 145.98, a PEG ratio of 3.33 and a beta of 0.41.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.